Stevanato Group (NYSE:STVN) PT Raised to $27.00

Stevanato Group (NYSE:STVN – Get Rating) had its price target upped by analysts at Morgan Stanley from $22.00 to $27.00 in a report issued on Friday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock.

Other research analysts have also issued reports about the company. Citigroup lifted their target price on Stevanato Group from $22.00 to $30.00 and gave the stock a “buy” rating in a report on Friday. KeyCorp boosted their target price on shares of Stevanato Group from $26.00 to $32.00 and gave the stock an “overweight” rating in a report on Friday. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of €26.80 ($28.51).

Stevanato Group Stock Performance

Shares of STVN opened at €25.40 ($27.02) on Friday. The firm has a market capitalization of $7.51 billion, a PE ratio of 45.36 and a beta of 0.66. The company has a quick ratio of 1.51, a current ratio of 2.00 and a debt-to-equity ratio of 0.18. The firm has a 50-day moving average price of €20.06 and a 200 day moving average price of €17.90. Stevanato Group has a 52-week low of €13.35 ($14.20) and a 52-week high of €25.72 ($27.36).

Stevanato Group (NYSE:STVN – Get Rating) last posted its quarterly earnings data on Thursday, March 2nd. The company reported €0.19 ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of €0.16 ($0.17) by €0.03 ($0.03). Stevanato Group had a net margin of 14.49% and a return on equity of 15.81%. The business had revenue of €292.10 million during the quarter, compared to analysts’ expectations of €271.89 million. During the same period last year, the firm posted $0.15 earnings per share. The business’s revenue was up 25.6% on a year-over-year basis. On average, sell-side analysts anticipate that Stevanato Group will post 0.59 earnings per share for the current fiscal year.

Institutional Trading of Stevanato Group

Institutional investors and hedge funds have recently bought and sold shares of the stock. UBS Group AG raised its holdings in shares of Stevanato Group by 79.9% during the first quarter. UBS Group AG now owns 1,799 shares of the company’s stock valued at $36,000 after acquiring an additional 799 shares during the period. US Bancorp DE purchased a new stake in shares of Stevanato Group in the second quarter valued at $40,000. First Horizon Advisors Inc. lifted its holdings in shares of Stevanato Group by 166.8% in the third quarter. First Horizon Advisors Inc. now owns 5,837 shares of the company’s stock valued at $98,000 after purchasing an additional 3,649 shares in the last quarter. Royal Bank of Canada purchased a new position in shares of Stevanato Group during the first quarter valued at $138,000. Finally, State of Wyoming raised its position in Stevanato Group by 79.7% during the fourth quarter. State of Wyoming now owns 8,015 shares of the company’s stock valued at $144,000 after buying an additional 3,556 shares during the period. Institutional investors and hedge funds own 10.27% of the company’s stock.

About Stevanato Group

(Get Rating)

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for pharma and healthcare. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines.